A 293% surge in search volume puts this obesity/T2D biotech in the spotlight. Here’s what it’s working on.
Polyrizon’s “biological mask” tech is catching attention as investors bet on its hydrogel nasal barrier platform.
PLRZ is up 159% on rising interest in its hydrogel nasal spray, which forms a shield against viruses and allergens.
Late-stage neuro-focused biotech’s lead therapy draws fresh investor attention.
Spruce Biosciences (SPRB) and Hepion Pharma (HEPA) pipelines also pick up traction today.
Upcoming Revita trial milestones, with first data expected this month, could position Fractyl Health as a post-GLP-1 weight-loss game-changer.
